Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2021 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Madurka I, Vishnevsky A, Soriano JB, Gans SJ, Ore DJS, Rendon A, Ulrik CS, Bhatnagar S, Krishnamurthy S, Mc Harry K, Welte T, Fernandez AA, Mehes B, Meiser K, Gatlik E, Sommer U, Junge G, Rezende E; Study group. Madurka I, et al. Infection. 2023 Jun;51(3):641-654. doi: 10.1007/s15010-022-01904-w. Epub 2022 Sep 14. Infection. 2023. PMID: 36104613 Free PMC article. Clinical Trial.
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Waters M, McKinnell JA, Kalil AC, Martin GS, Buchman TG, Theess W, Yang X, Lekkerkerker AN, Staton T, Rosenberger CM, Pappu R, Wang Y, Zhang W, Brooks L, Cheung D, Galanter J, Chen H, Mohan D, Peck MC; COVID-astegolimab-interleukin (IL) (COVASTIL) Study Group. Waters M, et al. Crit Care Med. 2023 Jan 1;51(1):103-116. doi: 10.1097/CCM.0000000000005716. Epub 2022 Nov 14. Crit Care Med. 2023. PMID: 36519984 Free PMC article. Clinical Trial.
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.
Bian H, Chen L, Zheng ZH, Sun XX, Geng JJ, Chen R, Wang K, Yang X, Chen SR, Chen SY, Xie RH, Zhang K, Miao JL, Jia JF, Tang H, Liu SS, Shi HW, Yang Y, Chen XC, Malhotra V, Nasir N, Khanum I, Mahmood F, Hamid S, Stadnik CMB, Itinose K, de Oliveira CCC, Dusilek C, Rivabem L, Cavalcante AJW, Lopes SS, Saporito WF, Fucci FJC, Simon-Campos JA, Wang L, Liu LN, Wang QY, Wei D, Zhang Z, Chen ZN, Zhu P. Bian H, et al. Among authors: stadnik cmb. Signal Transduct Target Ther. 2023 Jan 30;8(1):46. doi: 10.1038/s41392-023-01323-9. Signal Transduct Target Ther. 2023. PMID: 36717539 Free PMC article. Clinical Trial.
Dynamics of nosocomial SARS-CoV-2 transmissions: Facing the challenge of variants of concern in a Brazilian reference hospital.
Hoffmann AT, da Silva MS, Gularte JS, Pasqualotto AC, Proença Módena JL, Hansen AW, Stadñik CMB, Sukienik TCT, Demoliner M, Heldt FH, Filippi M, Pereira VMAG, de Marques CG, Kohler II, Quevedo DM, Spilki FR. Hoffmann AT, et al. Among authors: stadnik cmb. J Med Virol. 2023 Feb;95(2):e28446. doi: 10.1002/jmv.28446. J Med Virol. 2023. PMID: 36579775 Free PMC article.